Indication intelligence, analysis and sector perception

AxoGen (AXGN) proposes offering of 2.33 M shares priced at $7.50

October 6, 2016 4:19pm

BIG discount as AXGN shares had dropped -$0.21 or -2.49% to $8.24 and are DOWN -$0.48 to $7.76 - pre-market or -5.83% having been declining since 9/30’s $9.03

AXGN intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

The usual statement in the use of net proceeds of the offering - general working capital purposes and for expanded development of new nerve repair markets and products – and raise $17.5 M … i

As I stated Thursday in this market I'd be concerned with the discount to current pricing and was surprised when there were NO warrant attachments

JMP Securities LLC is acting as sole book-running manager for the offering. Dougherty & Company LLC is acting as a co-manager for the offering.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 29 min ago
RegMed Investors (RMi) Closing Bell: declining threads extend

10 hours 56 min ago
RegMed Investors’ (RMi) pre-open: who knows where share pricing goes as the sword of Damocles hangs overhead

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.